Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829141 | 0.85 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL91475 | 0.83 | ALDH1A1 (0.60) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL10276551 | 0.82 | SMN1; SMN2 (0.53) | NR3C2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2780621 | 0.81 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL29601179 | 0.81 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL25046270 | 0.81 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| Bromide SCHEMBL7030900 | 0.81 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL10310180 | 0.81 | KMT2A (0.53) | NR3C2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL12062262 | 0.81 | ALDH1A1 (0.60) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL20909676 | 0.80 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | claimed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | claimed |
| EP-3719012-B1 | N-[4-[(2-AMINO-4-PYRIDINYL)OXY]-3-FLUOROPHENYL]-3-(4-FLUOROPHENYL)-1,2,3,4-TETRAHYDRO-2,4-DIOXO-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AS C-MET/AXL INHIBITORS FOR THE TREATMENT OF TUMORS | MEDSHINE DISCOVERY INC (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | MEDSHINE DISCOVERY, INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3719012-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | Medshine Discovery Inc. (CN) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371395-A1 | URACIL COMPOUND AS C-MET/AXL INHIBITOR | AXL, MET, FLT3 | NR3C2 2401/4885NPC1 4245/4885RAB9A 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.